Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Ivonescimab in 2L Advanced HCC
NCT06196775Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and ivonescimab in hepatocellular carcinoma (HCC), sponsored by Harbin Medical University. Primary endpoint: Progression-Free Survival at 2 years. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cadonilimabivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06196775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196775.